688076 ST诺泰
交易中 02-06 10:51:03
资讯
新帖
简况
ST诺泰最新公告：全资子公司杭州澳赛诺奥格特韦钠原料药通过GMP符合性检查
证券之星 · 02-03 18:00
ST诺泰最新公告：全资子公司杭州澳赛诺奥格特韦钠原料药通过GMP符合性检查
ST诺泰（688076）披露2026年第一次临时股东会决议公告，2月3日股价下跌1.56%
证券之星 · 02-03 17:35
ST诺泰（688076）披露2026年第一次临时股东会决议公告，2月3日股价下跌1.56%
每周股票复盘：ST诺泰（688076）预计2025年营收19亿至20亿元
证券之星 · 02-01
每周股票复盘：ST诺泰（688076）预计2025年营收19亿至20亿元
ST诺泰：预计2025年全年归属净利润盈利3.1亿元至4.2亿元
证券之星 · 01-30
ST诺泰：预计2025年全年归属净利润盈利3.1亿元至4.2亿元
每周股票复盘：ST诺泰（688076）拟申请60亿授信额度
证券之星 · 01-18
每周股票复盘：ST诺泰（688076）拟申请60亿授信额度
每周股票复盘：ST诺泰（688076）收证监会处罚决定
证券之星 · 01-11
每周股票复盘：ST诺泰（688076）收证监会处罚决定
每周股票复盘：ST诺泰（688076）签10,210万美元供货合同
证券之星 · 01-02
每周股票复盘：ST诺泰（688076）签10,210万美元供货合同
ST诺泰（688076）披露日常经营重大合同进展，12月30日股价下跌0.53%
证券之星 · 2025-12-30
ST诺泰（688076）披露日常经营重大合同进展，12月30日股价下跌0.53%
ST诺泰：醋酸阿托西班注射液获药品注册证书
财中社 · 2025-12-09
ST诺泰：醋酸阿托西班注射液获药品注册证书
每周股票复盘：ST诺泰（688076）海外业务占比约63%
证券之星 · 2025-11-02
每周股票复盘：ST诺泰（688076）海外业务占比约63%
股市必读：ST诺泰（688076）10月30日披露最新机构调研信息
证券之星 · 2025-10-31
股市必读：ST诺泰（688076）10月30日披露最新机构调研信息
如意集团、ST诺泰等上市公司信披违规，受损投资者可关注索赔
21世纪经济报道 · 2025-10-29
如意集团、ST诺泰等上市公司信披违规，受损投资者可关注索赔
每周股票复盘：ST诺泰（688076）前三季度营收增21.95%
证券之星 · 2025-10-26
每周股票复盘：ST诺泰（688076）前三季度营收增21.95%
ST诺泰（688076）披露2025年第三季度报告，10月22日股价上涨0.3%
证券之星 · 2025-10-22
ST诺泰（688076）披露2025年第三季度报告，10月22日股价上涨0.3%
ST诺泰(688076.SH)发布前三季度业绩，归母净利润4.45亿元，增长26.92%
智通财经 · 2025-10-22
ST诺泰(688076.SH)发布前三季度业绩，归母净利润4.45亿元，增长26.92%
每周股票复盘：ST诺泰（688076）Q3净利预增5.62%至13.74%
证券之星 · 2025-10-12
每周股票复盘：ST诺泰（688076）Q3净利预增5.62%至13.74%
ST诺泰(688076.SH)发预增，预计第三季度归母净利润1.3亿元至1.4亿元，同比增加5.62%到13.74%
智通财经 · 2025-10-10
ST诺泰(688076.SH)发预增，预计第三季度归母净利润1.3亿元至1.4亿元，同比增加5.62%到13.74%
9月15日ST诺泰涨5.31%，招商蓝筹精选股票A基金重仓该股
证券之星 · 2025-09-15
9月15日ST诺泰涨5.31%，招商蓝筹精选股票A基金重仓该股
每周股票复盘：ST诺泰（688076）召开2025年第一次临时股东会
证券之星 · 2025-09-07
每周股票复盘：ST诺泰（688076）召开2025年第一次临时股东会
股市必读：ST诺泰（688076）8月29日披露最新机构调研信息
证券之星 · 2025-09-01
股市必读：ST诺泰（688076）8月29日披露最新机构调研信息
加载更多
公司概况
公司名称：
江苏诺泰澳赛诺生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2021-05-20
主营业务：
江苏诺泰澳赛诺生物制药股份有限公司的主营业务是多肽药物及小分子化药的自主研发与定制研发生产。公司的主要产品是多肽药物、创新药高级医药中间体及原料药。
发行价格：
15.57
{"stockData":{"symbol":"688076","market":"SH","secType":"STK","nameCN":"ST诺泰","latestPrice":35.01,"timestamp":1770346263000,"preClose":35.14,"halted":0,"volume":1271982,"delay":0,"changeRate":-0.0037,"floatShares":316000000,"shares":316000000,"eps":1.5779,"marketStatus":"交易中","change":-0.13,"latestTime":"02-06 10:51:03","open":34.95,"high":35.28,"low":34.61,"amount":44388100,"amplitude":0.0191,"askPrice":35.09,"askSize":5,"bidPrice":34.99,"bidSize":57,"shortable":0,"etf":0,"ttmEps":1.5779,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1770348600000},"marketStatusCode":2,"adr":0,"adjPreClose":35.14,"symbolType":"stock_kcb","openAndCloseTimeList":[[1770341400000,1770348600000],[1770354000000,1770361200000]],"highLimit":36.9,"lowLimit":33.38,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":316051897,"isCdr":false,"pbRate":3.57,"roa":"--","peRate":22.187718,"roe":"15.41%","epsLYR":1.88,"committee":0.716088,"marketValue":11065000000,"turnoverRate":0.004,"status":1,"floatMarketCap":11065000000},"requestUrl":"/m/hq/s/688076","defaultTab":"news","newsList":[{"id":"2608293824","title":"ST诺泰最新公告：全资子公司杭州澳赛诺奥格特韦钠原料药通过GMP符合性检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2608293824","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608293824?lang=zh_cn&edition=full","pubTime":"2026-02-03 18:00","pubTimestamp":1770112846,"startTime":"0","endTime":"0","summary":"ST诺泰(688076.SH)公告称，公司全资子公司杭州澳赛诺生物科技有限公司奥格特韦钠原料药正式通过GMP符合性检查，检查范围及相关车间、生产线包括原料药（奥格特韦钠）的一车间、六车间、九车间以及B原料药生产线。这表明公司具备领先的生产及质量管理体系，对公司持续开拓创新药原料药客户具有积极意义。但产品生产、销售受多种因素影响，对近期业绩和财务数据的影响存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300031643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2608541821","title":"ST诺泰（688076）披露2026年第一次临时股东会决议公告，2月3日股价下跌1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608541821","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608541821?lang=zh_cn&edition=full","pubTime":"2026-02-03 17:35","pubTimestamp":1770111327,"startTime":"0","endTime":"0","summary":"截至2026年2月3日收盘，ST诺泰报收于34.18元，较前一交易日下跌1.56%，最新总市值为108.03亿元。该股当日开盘34.72元，最高35.1元，最低33.93元，成交额达1.62亿元，换手率为1.5%。近日，ST诺泰发布《2026年第一次临时股东会决议公告》。公告显示，公司于2026年2月2日召开2026年第一次临时股东会，会议由董事会召集，董事长童梓权主持，采用现场与网络投票结合方式表决。出席会议股东共231人，代表表决权136,073,797股，占公司总表决权的43.0542%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020300029985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"gpt_icon":0},{"id":"2608072783","title":"每周股票复盘：ST诺泰（688076）预计2025年营收19亿至20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608072783","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608072783?lang=zh_cn&edition=full","pubTime":"2026-02-01 01:50","pubTimestamp":1769881822,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，ST诺泰报收于36.19元，较上周的37.95元下跌4.64%。本周，ST诺泰1月26日盘中最高价报38.3元。来自公司公告汇总：ST诺泰拟2026年申请不超60亿元综合授信额度。业绩披露要点ST诺泰发布业绩预告，预计2025年全年营业收入19亿元至20亿元。预计2025年全年归属净利润盈利3.1亿元至4.2亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"gpt_icon":0},{"id":"2607544016","title":"ST诺泰：预计2025年全年归属净利润盈利3.1亿元至4.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607544016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607544016?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:02","pubTimestamp":1769767343,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰发布业绩预告，预计2025年全年归属净利润盈利3.1亿元至4.2亿元。ST诺泰2025年三季报显示，前三季度公司主营收入15.27亿元，同比上升21.95%；归母净利润4.45亿元，同比上升26.92%；扣非净利润4.37亿元，同比上升23.2%；其中2025年第三季度，公司单季度主营收入4.79亿元，同比上升13.82%；单季度归母净利润1.34亿元，同比上升9.27%；单季度扣非净利润1.31亿元，同比上升4.38%；负债率53.15%，投资收益156.89万元，财务费用3731.46万元，毛利率68.46%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000032218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"gpt_icon":0},{"id":"2604925191","title":"每周股票复盘：ST诺泰（688076）拟申请60亿授信额度","url":"https://stock-news.laohu8.com/highlight/detail?id=2604925191","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604925191?lang=zh_cn&edition=full","pubTime":"2026-01-18 04:13","pubTimestamp":1768680786,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，ST诺泰报收于38.2元，较上周的38.87元下跌1.72%。本周，ST诺泰1月13日盘中最高价报39.84元。本周关注点公司公告汇总：ST诺泰拟在2026年度申请不超过600,000万元人民币的综合授信额度。公司公告汇总江苏诺泰澳赛诺生物制药股份有限公司将于2026年2月2日召开2026年第一次临时股东会，审议《关于向银行申请综合授信额度并提供担保的议案》。该项目募集资金承诺投资额为13,156.71万元，截至2025年12月31日累计投入7,799.63万元，使用比例为59.28%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800001260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"gpt_icon":0},{"id":"2602053584","title":"每周股票复盘：ST诺泰（688076）收证监会处罚决定","url":"https://stock-news.laohu8.com/highlight/detail?id=2602053584","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602053584?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:25","pubTimestamp":1768069510,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，ST诺泰报收于38.87元，较上周的37.7元上涨3.1%。本周，ST诺泰1月9日盘中最高价报39.32元。ST诺泰当前最新总市值122.85亿元，在化学制药板块市值排名49/150，在两市A股市值排名1683/5182。本周关注点公司公告汇总：ST诺泰于2025年12月17日收到证监会《行政处罚决定书》及上交所纪律处分决定。公司公告汇总南京证券作为保荐机构，对诺泰生物2025年1月1日至现场检查期间的规范运作进行了现场检查。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2600103632","title":"每周股票复盘：ST诺泰（688076）签10,210万美元供货合同","url":"https://stock-news.laohu8.com/highlight/detail?id=2600103632","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600103632?lang=zh_cn&edition=full","pubTime":"2026-01-02 02:42","pubTimestamp":1767292930,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，ST诺泰报收于38.55元，较上周的39.07元下跌1.33%。本周，ST诺泰12月23日盘中最高价报39.81元。ST诺泰当前最新总市值119.15亿元，在化学制药板块市值排名44/150，在两市A股市值排名1638/5181。本周关注点公司公告汇总：ST诺泰全资子公司签订累计金额约10,210万美元的主服务及供货合同。2025年度合同实际履行金额约2,000万美元，占公司2024年度经审计营业收入的8.83%，占定制类产品及服务收入的29.05%。合同金额为客户采购量指引，不构成最低采购承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200000644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2595640718","title":"ST诺泰（688076）披露日常经营重大合同进展，12月30日股价下跌0.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595640718","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595640718?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:18","pubTimestamp":1767104301,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，ST诺泰报收于37.67元，较前一交易日下跌0.53%，最新总市值为119.06亿元。该股当日开盘37.82元，最高37.86元，最低37.65元，成交额达7778.39万元，换手率为0.65%。2025年度合同实际履行金额约2,000万美元，占公司2024年度经审计营业收入的8.83%，占定制类产品及服务收入的29.05%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000044062.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2590928343","title":"ST诺泰：醋酸阿托西班注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590928343","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590928343?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:44","pubTimestamp":1765280640,"startTime":"0","endTime":"0","summary":"12月9日，ST诺泰（维权）发布公告，公司近日收到国家药品监督管理局核准签发的醋酸阿托西班注射液的《药品注册证书》，证书编号为2025S03644、2025S03645。 醋酸阿托西班注射液是一种选择性缩宫素受体拮抗剂，适用于有早产指征的妊娠妇女，用于推迟即将出现的早产。 2025年前三季度，ST诺泰实现收入15.27亿元，归母净利润4.45亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2025-12-09/doc-inhafezz1312149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2580479004","title":"每周股票复盘：ST诺泰（688076）海外业务占比约63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580479004","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580479004?lang=zh_cn&edition=full","pubTime":"2025-11-02 04:52","pubTimestamp":1762030328,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，ST诺泰报收于38.88元，较上周的39.62元下跌1.87%。本周，ST诺泰10月27日盘中最高价报40.22元。ST诺泰当前最新总市值122.88亿元，在化学制药板块市值排名47/151，在两市A股市值排名1558/5163。本周关注点来自机构调研要点：截至2024年年报数据，公司海外业务占比约63%。公司601车间已投产，602车间目前正在进行验证批生产。二级市场股价变化受多方面因素影响，公司目前生产经营情况正常。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2579109684","title":"股市必读：ST诺泰（688076）10月30日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2579109684","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579109684?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:22","pubTimestamp":1761862967,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，ST诺泰报收于37.85元，下跌0.66%，换手率0.81%，成交量2.55万手，成交额9655.27万元。因与客户签有保密协议，无法透露具体客户信息。601车间已投产，602车间正在进行验证批生产。截至2024年年报数据，公司海外业务营收占比约63%，高于国内业务。关于证监会行政处罚事项，公司表示如收到相关进展结果将依法及时披露。司美格鲁肽注射液目前处于临床阶段，推进节奏存在不确定性，后续进展将依规披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100007978.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2579900661","title":"如意集团、ST诺泰等上市公司信披违规，受损投资者可关注索赔","url":"https://stock-news.laohu8.com/highlight/detail?id=2579900661","media":"21世纪经济报道","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579900661?lang=zh_cn&edition=full","pubTime":"2025-10-29 22:15","pubTimestamp":1761747300,"startTime":"0","endTime":"0","summary":" 近期，如意集团（维权）、ST诺泰（维权）、太原重工（维权）、*ST云创等多家上市公司因涉嫌信息披露违规相继被立案调查或行政处罚。从财务造假到隐瞒关联交易，从业绩预告“变脸”到重大诉讼披露滞后，这些违规行为不仅破坏了市场秩序，更让不少投资者蒙受损失。10月29日，衡财保·炜衡金融315团队的廖律师向投资快报记者表示，按照证券法等相关规定，建议不慎“踩雷”的投资者积极依法索赔。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2025-10-29/doc-infvqrtz3101909.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-10-29/doc-infvqrtz3101909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0247","688076","002193"],"gpt_icon":0},{"id":"2578504968","title":"每周股票复盘：ST诺泰（688076）前三季度营收增21.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578504968","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578504968?lang=zh_cn&edition=full","pubTime":"2025-10-26 02:20","pubTimestamp":1761416420,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，ST诺泰报收于39.62元，较上周的36.11元上涨9.72%。来自业绩披露要点：2025年前三季度营业收入152.72亿元，同比增长21.95%。股本股东变化股东户数变动截至2025年9月30日，ST诺泰股东户数为1.57万户，较6月30日减少3060户，减幅16.3%。业绩披露要点ST诺泰：2025年第三季度报告2025年前三季度，公司实现营业收入1,527,177,738.82元，同比增长21.95%；归属于上市公司股东的净利润444,542,384.12元，同比增长26.92%。研发投入合计348,643,501.76元，同比增长63.27%，研发费用占营业收入比例达22.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102600000416.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"gpt_icon":0},{"id":"2577395601","title":"ST诺泰（688076）披露2025年第三季度报告，10月22日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577395601","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577395601?lang=zh_cn&edition=full","pubTime":"2025-10-22 22:34","pubTimestamp":1761143653,"startTime":"0","endTime":"0","summary":"截至2025年10月22日收盘，ST诺泰报收于37.2元，较前一交易日上涨0.3%，最新总市值为117.57亿元。该股当日开盘37.09元，最高37.48元，最低36.99元，成交额达7950.5万元，换手率为0.68%。近日，ST诺泰发布《2025年第三季度报告》，披露了公司前三季度主要财务数据。报告显示，年初至报告期末，公司实现营业收入1,527,177,738.82元，同比增长21.95%；归属于上市公司股东的净利润为444,542,384.12元，同比增长26.92%。研发投入合计为348,643,501.76元，同比增长63.27%，占营业收入的比例为22.83%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102200037723.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"gpt_icon":0},{"id":"2577035092","title":"ST诺泰(688076.SH)发布前三季度业绩，归母净利润4.45亿元，增长26.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577035092","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577035092?lang=zh_cn&edition=full","pubTime":"2025-10-22 18:15","pubTimestamp":1761128134,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST诺泰(688076.SH)发布2025年三季度报告，该公司前三季度营业收入为15.27亿元，同比增长21.95%。归属于上市公司股东的净利润为4.45亿元，同比增长26.92%。归属于上市公司股东的扣除非经常性损益的净利润为4.37亿元，同比增长23.20%。基本每股收益为1.42元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358196.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ST诺泰(688076.SH)发布前三季度业绩，归母净利润4.45亿元，增长26.92%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688076"],"gpt_icon":0},{"id":"2574457196","title":"每周股票复盘：ST诺泰（688076）Q3净利预增5.62%至13.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574457196","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574457196?lang=zh_cn&edition=full","pubTime":"2025-10-12 01:52","pubTimestamp":1760205131,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，ST诺泰报收于40.1元，较上周的41.58元下跌3.56%。本周，ST诺泰10月9日盘中最高价报41.8元。ST诺泰当前最新总市值126.74亿元，在化学制药板块市值排名43/150，在两市A股市值排名1518/5158。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2574237851","title":"ST诺泰(688076.SH)发预增，预计第三季度归母净利润1.3亿元至1.4亿元，同比增加5.62%到13.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574237851","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574237851?lang=zh_cn&edition=full","pubTime":"2025-10-10 16:24","pubTimestamp":1760084656,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST诺泰(688076.SH)发布第三季度业绩预告，预计2025年第三季度实现归属于母公司所有者的净利润1.3亿元至1.4亿元，同比增加5.62%到13.74%。报告期内，公司贯彻“时间领先、技术领先”的经营理念，各项主营业务有序开展，净利润实现稳健增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1353600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"ST诺泰(688076.SH)发预增，预计第三季度归母净利润1.3亿元至1.4亿元，同比增加5.62%到13.74%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688076"],"gpt_icon":0},{"id":"2567219457","title":"9月15日ST诺泰涨5.31%，招商蓝筹精选股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2567219457","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567219457?lang=zh_cn&edition=full","pubTime":"2025-09-15 16:25","pubTimestamp":1757924719,"startTime":"0","endTime":"0","summary":"证券之星消息，9月15日ST诺泰涨5.31%，收盘报43.99元，换手率3.17%，成交量10.01万手，成交额4.32亿元。重仓ST诺泰的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为招商基金的招商蓝筹精选股票A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500020534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2565517199","title":"每周股票复盘：ST诺泰（688076）召开2025年第一次临时股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2565517199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565517199?lang=zh_cn&edition=full","pubTime":"2025-09-07 01:19","pubTimestamp":1757179149,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，ST诺泰报收于40.99元，较上周的42.8元下跌4.23%。本周，ST诺泰9月2日盘中最高价报44.8元。本周关注点公司公告汇总：ST诺泰于2025年9月5日召开临时股东会，审议通过变更会计师事务所、取消监事会并修订公司章程等议案。公司公告汇总江苏诺泰澳赛诺生物制药股份有限公司于2025年9月5日召开2025年第一次临时股东会，会议由董事会召集，董事长童梓权主持，采用现场与网络投票结合方式召开。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000090.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0},{"id":"2564857519","title":"股市必读：ST诺泰（688076）8月29日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2564857519","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564857519?lang=zh_cn&edition=full","pubTime":"2025-09-01 04:53","pubTimestamp":1756673588,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，ST诺泰报收于42.8元，上涨0.19%，换手率2.8%，成交量8.86万手，成交额3.78亿元。当日关注点来自交易信息汇总：8月29日主力资金净流出3739.01万元，占总成交额9.9%。来自机构调研要点：公司已与深势科技达成全方位战略合作，布局AI制药及合成生物学领域。公司BD团队正积极拓展海外bigpharma业务合作，如有进展将依规披露。目前与礼来、诺和诺德尚无业务关系。会议采取现场与网络投票相结合方式召开。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100000651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1770346295464,"stockEarnings":[{"period":"1week","weight":-0.0521},{"period":"1month","weight":-0.0811},{"period":"3month","weight":-0.0731},{"period":"6month","weight":-0.244},{"period":"1year","weight":0.0124},{"period":"ytd","weight":-0.0679}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":-0.0019},{"period":"3month","weight":0.0196},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.2621},{"period":"ytd","weight":0.027}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏诺泰澳赛诺生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15710人(较上一季度减少16.30%)","perCapita":"20117股","listingDate":"2021-05-20","address":"江苏省连云港市连云区经济技术开发区临浦路28号","registeredCapital":"31605万元","survey":" 江苏诺泰澳赛诺生物制药股份有限公司的主营业务是多肽药物及小分子化药的自主研发与定制研发生产。公司的主要产品是多肽药物、创新药高级医药中间体及原料药。","listedPrice":15.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST诺泰(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST诺泰(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST诺泰,688076,ST诺泰股票,ST诺泰股票老虎,ST诺泰股票老虎国际,ST诺泰行情,ST诺泰股票行情,ST诺泰股价,ST诺泰股市,ST诺泰股票价格,ST诺泰股票交易,ST诺泰股票购买,ST诺泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST诺泰(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST诺泰(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}